Sheraton Tel Aviv Hotel & Towers
115 Hayarkon Street
Tel Aviv 63573 Israel
http://www.sheratontelaviv.com/


A special rate is being offered at the Sheraton Tel Aviv Hotel & Towers for conference attendees. To take advantage of this special rate, please make your reservations here.

Conference Chair
Larry Norton, MD
Memorial Sloan-Kettering Cancer Center
New York, New York, United States


Keynote Lecture
Mary-Claire King, PhD
University of Washington School of Medicine
Seattle, Washington, United States


Session Chairs
Fatima Cardoso, MD
The Champalimaud Cancer Center
Lisbon, Portugal


Judy Garber, MD, MPH
Dana-Farber Cancer Institute
Boston, Massachusetts, United States


Bella Kaufman, MD
Sheba Medical Center
Tel Hashomer, Israel

Faculty Yoav Barnea, MD Tel Aviv Sourasky Medical Center Tel Aviv, Israel Merav Ben-David, MD Sheba Medical Center Tel Hashomer, Israel Eitan Friedman, MD, PhD Sheba Medical Center Tel Hashomer, Israel Mordechai Gutman, MD Sheba Medical Center Tel Hashomer, Israel Ephrat Levy-Lahad, MD Shaare Zedek Medical Center Jerusalem, Israel

Jan Lubinski, MD, PhD Pomeranian Medical University Szczecin, Poland Dror Meirow, MD Sheba Medical Center Tel Hashomer, Israel Cristiana Sessa, MD Ospedale San Giovanni Bellinzona, Switzerland Harmine Zonderland, MD, PhD Academic Medical Center Amsterdam, the Netherlands

This educational activity is designed for surgeons, radiologists, medical oncologists, radiation oncologists, surgical oncologists, pathologists, and other healthcare providers involved and/or interested in the management of patients with BRCA mutations.

Upon completion of this educational activity, participants should be able to:

• Summarize the clinical challenges in the management of patients with BRCA mutations
• Describe genetic factors associated with BRCA mutations, and analyze the role of genetic counseling in patients undergoing BRCA mutation testing
• Outline appropriate options for breast and ovarian cancer prevention in BRCA mutation carriers
• Select optimal screening methods for breast cancer in patients with BRCA mutations
• Discuss management of reproductive concerns in patients with BRCA mutations
• Analyze local therapy options for patients with BRCA mutation–associated breast cancer
• Explain the therapeutic rationale for chemotherapy and targeted agents in patients with BRCA mutation–associated breast and ovarian cancer, and examine recent clinical trial data supporting the use of these agents

Thursday, 18 November 2010

13.30-13.40		Welcome and introduction Larry Norton, MD, and Bella Kaufman, MD
13.40-14.10		Keynote Lecture: Genomic Analysis of Inherited Breast and Ovarian Cancer Mary-Claire King, PhD
14.10-14.15		Q&A
14.15-15.50		Session I: Genetics and Risk for Breast and Ovarian Cancer Chair: Larry Norton, MD
14.15-14.35		Genetic predisposition for breast and ovarian cancer Eitan Friedman, MD, PhD
14.35-14.55		BRCA screening program: Polish experience Jan Lubinski, MD, PhD
14.55-15.15		Genetic counseling in practice Ephrat Levy-Lahad, MD
15.15-15.35		Geographic implications for BRCA mutations Faculty panel: Larry Norton, MD (moderator) Ephrat Levy-Lahad, MD Jan Lubinski, MD, PhD
15.35-15.50		Discussion, questions, and pearls of the session Larry Norton, MD
15.50-16.10		Break
16.10-18.05		Session II: Breast and Ovarian Cancer Detection and Prevention in BRCA Mutation Carriers Chair: Bella Kaufman, MD
16.10-16.30		Risk reduction surgery Mordechai Gutman, MD
16.30-16.50		The role of reconstructive surgery following risk reduction mastectomy Yoav Barnea, MD
16.50-17.10		Chemoprevention Judy Garber, MD, MPH
17.10-17.30		Diagnosis and radiologic surveillance of BRCA carriers   Harmine Zonderland, MD, PhD
17.30-17.50		Managing fertility concerns Dror Meirow, MD
17.50-18.05		Discussion, questions, and pearls of the session Bella Kaufman, MD
18.30-19.30		Reception
Friday, 19 November 2010
8.00-9.00		Breakfast
9.00-9.05		Introduction to Day 2 program Judy Garber, MD, MPH, and Fatima Cardoso, MD
9.05-12.00		Session III: Management of Breast and Ovarian Cancer in BRCA Carriers Chair: Judy Garber, MD, MPH
9.05-9.45		Local therapy of breast cancer in BRCA carriers: Clinical dilemmas · Surgery   Mordechai Gutman, MD · Radiotherapy   Merav Ben-David, MD
9.45-9.55		Q&A
9.55-10.15		Conventional chemotherapy and non-PARP targeted strategies for BRCA deficient breast cancer Judy Garber, MD, MPH
10.15-10.20		Q&A
10.20-10.40		Break
10.40-11.00		Systemic therapy options for BRCA deficient ovarian cancer Cristiana Sessa, MD
11.00-11.05		Q&A
11.05-11.25		Role of PARP inhibitors in breast and ovarian cancer Judy Garber, MD, MPH
11.25-11.45		Experience with PARP inhibitors in breast and ovarian cancer patients in Israel: Investigator perspective Bella Kaufman, MD
11.45-11.50		Q&A
11.50-12.00		Discussion, questions, and pearls of the session Judy Garber, MD, MPH
12.00-13.00		Lunch
13.00-14.30		Multidisciplinary tumor board Chair: Fatima Cardoso, MD
14.30		Concluding remarks and key messages Larry Norton, MD